A US FDA complete response letter (CRL) for Allergan PLC's ulipristal acetate in the treatment of abnormal uterine bleeding in women with uterine fibroids removes an overhang on the company's effort to sell its women's health unit, but it will also negatively impact any potential valuation of the business.
The company announced the receipt of a CRL in response to a new drug application (NDA) for ulipristal Aug. 21,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
